



BRIEF QUESTIONS
AND ANSWERS
ON CURRENT
CLINICAL
CONTROVERSIES

Q: Should we offer semen cryopreservation to men with testicular cancer?

FABIO F. PASQUALOTTO, MD

Center for Advanced Research in Human Reproduction and Infertility, Urological Institute, Cleveland Clinic

ASHOK AGARWAL, PHD

Center for Advanced Research in Human Reproduction and Infertility, Urological Institute, Director, Andrology Laboratory, Cleveland Clinic

A: YES, ALL MEN WITH testicular cancer should have the option of banking sperm before starting chemotherapy or radiation therapy if they want to retain the potential to have children.

Semen cryopreservation has become particularly important in recent years for several reasons. Long-term survival rates have increased: more than 90% of patients with testicular cancer now survive longer than 5 years,¹ making treatment-related complications such as infertility more of an issue. Assisted reproductive techniques have also improved, and cryopreserved semen from men with cancer can be used successfully to initiate pregnancies.² In addition, semen cryopreservation helps patients maintain their morale during stressful treatment by providing hope that they may still be able to have children.

■ HOW COMMON IS TESTICULAR CANCER?

The incidence of testicular cancer has increased worldwide during the last 4 to 5 decades. In industrialized countries, testicular tumors are the most common solid malignant disease among men aged 20 to 34.^{3,4} About 5,600 cases of testicular cancer are diagnosed annually in the United States.¹

■ HOW CANCER TREATMENT DIMINISHES FERTILITY

Treatment can diminish fertility,¹ despite modifications designed to preserve spermatogenesis.

Radiation therapy can be toxic to the gonads, even though shielding the gonads helps preserve spermatogenesis and leads to a certain degree of recovery in spermatogenesis over time.^{1,5-7} Many patients who undergo radiotherapy remain azoospermic for extended periods. Although testicular shielding may decrease the scatter radiation dose by 50%, significant doses can still reach the testis by internal body scatter. Thachil et al⁸ found that 32% of patients with testicular seminoma became azoospermic and 50% experienced severe oligospermia after receiving a total of 2,500 cGy to the periaortic area in 20 fractions. Of this dose, 325 cGy, or 13% of the total dose, was directed at the upper scrotum, and some of this dose likely reached the gonads by internal body scatter.

Ionizing radiation may also cause genetic mutations that accumulate as the total dose increases and hamper the ability of spermatozoa to initiate a viable pregnancy. An increased frequency of numerical and structural chromosomal abnormalities has been shown to persist up to 5 years after radiation therapy.⁹

Chemotherapy works by interrupting obligatory cell processes such as DNA synthesis and folate metabolism in rapidly dividing malignant cells.⁵ But it also interferes with spermatogenesis and the endocrine and exocrine functions of the male reproductive system.^{7,10}

A number of factors may influence gonadal function: the drug used, the dose, the number of chemotherapy cycles, and adjuvant therapy after treatment.

Many chemotherapeutic agents are powerful testicular toxins; these include busulfan, chlorambucil, cyclophosphamide, cisplatin, thiotepa, and procarbazine. Alkylating agents can cause irreversible azoospermia. Patients with testicular germ cell tumors often receive cisplatin-based chemotherapy, which causes

Offer the option of sperm banking before radiation or chemotherapy



oligospermia in 16% and azospermia in 20% of men who have normal sperm counts before chemotherapy.

The depletion of the germinal epithelium is progressive and dose-dependent, and alterations in Sertoli cell and Leydig functions are reflected by elevations in gonadotropin-releasing hormone, luteinizing hormone, and follicle-stimulating hormone.¹¹


Recovery of spermatogenesis can be slow and sometimes incomplete after chemotherapy for testicular cancer. At 2 years after chemotherapy, spermatogenesis has returned in only 48% of men.¹²

Retroperitoneal lymph node dissection can cause ejaculatory dysfunction through emission failure, retrograde ejaculation, or both.^{1,5,10}

■ HOW ASSISTED REPRODUCTION HAS IMPROVED

Some have questioned the use of semen cryopreservation in patients with testicular cancer because these patients have poorer semen quality than men without this disease.^{2,12-15} Even before treatment, 50% to 60% of men with testicular cancer have substantial reductions in their total sperm counts¹¹; their motile sperm counts are lower before freezing and after thawing, and they have lower sperm motility.^{14,15}

However, new assisted reproductive techniques such as intracytoplasmic sperm injection (ICSI) can overcome the poor semen quality and may result in pregnancy.^{16,17} Goldschlag et al¹⁸ reported that of 41 partners of patients with testicular cancer who attempted to become pregnant with ICSI using cryobanked semen, 22 (54%) achieved a normal clinical pregnancy, and 19 (46%) went on to delivery. We have seen similar results in our program.

Therefore, even samples from men with testicular cancer that are too poor in quality for traditional assisted reproductive techniques (intrauterine insemination or conventional in vitro fertilization) may still be adequate for ICSI. Only one viable sperm per oocyte is required for ICSI. Semen cryopreservation is thus a viable alternative for any patient with testicular cancer. 

■ REFERENCES

1. Turek PJ, Lowther DN, Carroll PR. Fertility issues and their management in men with testis cancer. *Urol Clin North Am* 1998; 25:5217-5231.
2. Hallak J, Hendin BH, Thomas AJ, Jr., Agarwal A. Investigation of fertilizing capacity of cryopreserved spermatozoa from patients with cancer. *J Urol* 1998; 159:1217-1220.
3. Oesterlind A. Diverging trends in incidence and mortality of testicular cancer in Denmark, 1943-1982. *Br J Cancer* 1986; 53:501-505.
4. Ekblom A, Akre O. Increasing incidence of testicular cancer-birth cohort effects. *APMIS* 1998; 106:225-231.
5. Pont J, Albrecht W. Fertility after chemotherapy for testicular germ cell cancer. *Fertil Steril* 1997; 68:1-5.
6. Costabile, RA, Spevak, M. Cancer and male factor infertility. *Oncology* 1998; 12:557-568.
7. Meirou D, Schenker JG. Cancer and male infertility. *Hum Reprod* 1995; 10:2017-2022.
8. Thachil JV, Jewett MA, Rider WD. The effects of cancer and cancer therapy on male fertility. *J Urol* 1981; 126:141-145.
9. Martin RH, Rademaker A, Hildebrand K, et al. A comparison of chromosomal aberrations induced by in vivo radiotherapy in human sperm and lymphocytes. *Mutat Res* 1989; 226:21-30.
10. Botchan A, Hauser R, Yogev L, et al. Testicular cancer and spermatogenesis. *Hum Reprod* 1997; 12:755-758.
11. Monga M, Zeitung J. What are the effects of cancer therapy on fertility? *Contemp Urol* 1999; 11:21-33.
12. Agarwal A, Tolentino MV, Sidhu RS, et al. Effect of cryopreservation on semen quality in patients with testicular cancer. *Urol* 1995; 46:382-389.
13. Lass A, Akagbosu F, Abusheikha N, et al. A programme of semen cryopreservation for patients with malignant disease in a tertiary infertility centre: lessons from 8 years' experience. *Hum Reprod* 1998; 13:3256-3261.
14. Lass A, Abusheikha N, Akagbosu F, Brinsden P. Cancer patients should be offered semen cryopreservation. *BMJ* 1999; 318:1556.
15. Hallak J, Kolettis PN, Seckon VS, Thomas AJ Jr., Agarwal A. Sperm cryopreservation in patients with testicular cancer. *Urol* 1999; 54:894-899.
16. Chen SU, Ho HN, Chen HF, Huang SC, Le TY, Yang YS. Pregnancy achieved by intracytoplasmic sperm injection using cryopreserved semen from a man with testicular cancer. *Hum Reprod* 1996; 11:2645-2647.
17. Yavetz H, Hauser R, Botchan A, et al. Pregnancy resulting from frozen-thawed embryos achieved by intracytoplasmic sperm injection of cryopreserved sperm cells extracted from an orchidectomized, seminoma bearing testis causing obstructive azospermia. *Hum Reprod* 1997; 12:2836-2838.
18. Goldschlag DE, Kump LM, Davis OK, Rosenwaks Z. Pregnancies achieved through ICSI using cryopreserved semen from men with malignant neoplasms—The Cornell Experience [abstract]. Annual Meeting of American Society for Reproductive Medicine, 1998, Abstract O-198, San Francisco, CA.

ADDRESS: Ashok Agarwal, PhD, Andrology Laboratory, A19, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, e-mail agarwaa@ccf.org.

New techniques can overcome poor sperm quality